<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab</h1>
  <ul>
<li>About Ovarian Cancer More than 324,000 women were diagnosed with ovarian cancer worldwide in 2022.1 The median overall survival for advanced ovarian cancer following recurrence can be as little as two years, with a five-</li>
<li>Updated 2022.</li>
<li>Updated 2021.</li>
<li>2018; 9(5):872.</li>
<li>2011;11(8), 708–713.</li>
<li>2021; 137(1): 108-121.</li>
<li>Accessed September 2025.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/raludotatug-deruxtecan-granted-breakthrough-therapy-110000942.html">Source</a> · 2025-09-15T11:00:00+00:00</p>
</body>
</html>